On November 13, the FDA approved pertuzumab-dpzb as an interchangeable biosimilar to pertuzumab. For more information, read the FDA announcement and visit the Shanghai Henlius Biologics website.
On November 13, the FDA approved pertuzumab-dpzb as an interchangeable biosimilar to pertuzumab.
For more information, read the FDA announcement and visit the Shanghai Henlius Biologics website.
Posted on 11/14/2025
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
